Our aforementioned preclinical results confirmed the structural modeling of EGFR-D770>GY (Figure 1A) and led us to speculate that patients with advanced lung cancers harboring EGFR exon 20 insertion mutations with a G770 equivalence could respond to afatinib, dacomitinib, poziotinib and mobocertinib, but would not derive clinical benefit from gefitinib, erlotinib or osimertinib. Here, EGFR is linked to lung cancer.